Barbera J et al. Large-scale quarantine following biological terrorism in the United States: scientific examination, logistic and legal limits, and possible consequences. Journal of the American Medical Association, 2001, 286:2711 - 2717.
Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerging Infectious Diseases, 2002, 8:833 - 841 (disponible en http://www.cdc.gov/ncidod/EID/vol8no8/pdf/01-0516.pdf
Cieslak TJ et al. Immunization against potential biological warfare agents. Clinical Infectious Diseases, 2000, 30:843 - 850.
Guidance document on the use of medicinal products for the treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. London, European Agency for the Evaluation of Medicinal Products, 2002 (document CPMP/4048/01; disponible en http://www.emea.eu.int/pdfs/human/bioterror/404801.pdf
Richard P et al. Guide to infection control in the hospital: an official publication of the International Society for Infectious Diseases. Hamilton, ON, BC Decker, 1988.
Treatment of biological warfare agent casualties. Field Manual 8-284, NAVMED P-5042, Air Force Manual (Interservice) 44-156, Marine Corps MCRP 4-11.1C, Headquarters, Departments of the Army, the Navy, and the Air Force, and Commandant Marine Corps, Washington, DC, 17 July 2000.